Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI at OM1, talked with MHE editors about the importance of patient acceptance in the adoption of AI in healthcare, emphasizing the need for trust and transparency in AI tools.
Zabinksi highlighted the growing familiarity of patients with AI through general use in daily life but cautioned the importance of building trust in healthcare. He stressed that AI should complement and support clinicians rather than replace them.
In addition, he shared supporting evidence of increasing comfort with AI among patients but noted the ongoing need for trust-building efforts.
"It's a very powerful set of tools that give significant advantages in some areas over tools that exist, but it's not perfect. It's not magic, it's not always right," he said.
Regarding dermatology's acceptance of AI, Zabinski noted the field's interest in innovative data-driven tools while maintaining a practical outlook on their usefulness in practice.
He suggested that dermatology, like other medical specialties, is not yet saturated with AI tools but is on the path towards adoption.
Though, there is potential of AI in dermatology, particularly in image analysis for diagnosing rare diseases and closing gaps in diagnosis and treatment, he said.
When discussing the visual component of dermatology, Zabinski acknowledged the advantages of AI in analyzing visual information to aid in triage and diagnosis.
However, he cautioned against bias and misrepresentation in AI training and application, especially concerning skin types and appearances.
Zabinski stressed the importance of representative training data and careful use of AI tools to avoid causing harm and undermining trust in dermatology.
Microneedling Combined with Other Vitiligo Therapies Offers Promising Treatment for Skin Disease
April 10th 2024Researchers of a study conducted a double-blind intervention that aimed to assess the effectiveness and tolerance of a new approach for vitiligo treatment using meso-microneedling with 5% N-acetylcysteine (NAC) ampoules and topical 4.7% NAC, compared to microneedling alone.
Read More
Positive Results for Ruxolitinib Cream in Children with Atopic Dermatitis Presented in Ongoing Study
March 18th 2024Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.
Read More
Opzelura Provides Benefit in Atopic Dermatitis in Real-World Studies | AAD 2024
March 8th 2024Physicians switch to Opzelura (ruxolitinib) when other therapies fail to help patients with atopic dermatitis, according to a new analysis presented at the annual meeting of the American Academy of Dermatology.
Read More
Reasons for attending the AAD meeting | AAD 2024
March 7th 2024John Barbieri, assistant professor at Harvard Medical School, is looking forward to the upcoming 2024 American Academy of Dermatology meeting, which runs from March 8-12 in San Diego. Barbieri is particularly showing interest in late-breaking abstracts and trial data and hoping to see cutting-edge information from pivotal clinical trials.
Read More